|
|
| | CELECOXIB-D7 Basic information |
| Product Name: | CELECOXIB-D7 | | Synonyms: | CELECOXIB-D7;4-[5-[2,3,5,6-tetradeuterio-4-(trideuteriomethyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide;[2H7]-Celecoxib;Celecoxib D7Q: What is
Celecoxib D7 Q: What is the CAS Number of
Celecoxib D7 Q: What is the storage condition of
Celecoxib D7 Q: What are the applications of
Celecoxib D7;Celecoxiβ-d7;4-[5-[4-(methyl-d3)phenyl-2,3,5,6-d4]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide | | CAS: | 544686-21-7 | | MF: | C17H7D7F3N3O2S | | MW: | 388.42 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | CELECOXIB-D7 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 76 mg/ml,Ethanol: 33 mg/ml | | form | A solid | | color | Off-white to gray |
| | CELECOXIB-D7 Usage And Synthesis |
| Description | Celecoxib-d7 is intended for use as an internal standard for the quantification of celecoxib by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC50s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively). It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition. Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events. | | Uses | Celecoxib-d7 is the labeled analogue of Celecoxib (C251000), a selective cyclooxygenase-2 (COX-2) inhibitor. Anti-inflammatory. Used in treatment of familial adenomatous polyposis. |
| | CELECOXIB-D7 Preparation Products And Raw materials |
|